BMB-105 is a serotonin 5-HT<sub>2C</sub> receptor agonist which is under development for the treatment of excessive appetite and other symptoms in PraderâÂÂWilli syndrome. It is taken orally.
The drug is described as a highly selective biased agonist of the serotonin 5-HT<sub>2C</sub> receptor, with activation of the G<sub>q</sub> signaling pathway but minimal ò-arrestin recruitment.
BMB-105 is under development by Bright Minds Biosciences. As of November 2025, it is in phase 1 clinical trials. The drug is described as a follow-on drug to Bright Mind Bioscience's more advanced candidate BMB-101 and as a potential "best-in-class" medication.
The exact chemical structure of BMB-105 does not yet appear to have been disclosed. However, it is known to be a 2-phenylcyclopropylmethylamine (PCPMA) derivative similarly to BMB-101 and to share structural commonalities with tranylcypromine.